This Phase 2a/2 study evaluates the safety, tolerability, and efficacy of neoadjuvant and adjuvant NAI, hAd5-HPV vaccine (IBRX-042), and nab-paclitaxel in participants with locally advanced HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). The study includes a Phase 2a safety lead-in followed by a randomized Phase 2 comparison of a de-intensified experimental chemoradiation approach versus standard-of-care chemoradiation.
Age ≥ 18 years old.
Able to understand and provide a signed informed consent that fulfills the relevant Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Histologically confirmed squamous cell carcinoma of the oropharynx that is HPV-positive (p16 immunohistochemistry positive and/or HPV DNA positive). Patients with cervical lymph node metastases from an unknown primary can be included if p16-positive and likely OPSCC origin.
Ability to attend required study visits and return for adequate follow-up, as required by this protocol.
Agreement to practice effective contraception for female participants of child-bearing potential and non-sterile males. Per cisplatin prescribing information, female participants of child-bearing potential must agree to use effective contraception for up to 14 months and non-sterile male participants must agree to use a condom for up to 11 months after last dose of cisplatin. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), orals, injectables, 2 forms of barrier methods (eg, condom, diaphragm) used with spermicide, intrauterine devices (IUDs), and hormonal therapy.
HPV-negative or Non-OPSCC: Tumors that are p16-negative or not in the oropharynx are excluded.
Any evidence of distant metastases (M1 disease) excludes the patient, since the trial is for curative-intent local/regional therapy.
Parallel
Nogapendekin Alfa Inbakicept (NAI)
DrugNAI 1.2 mg administered subcutaneously as part of the experimental treatment regimen.
hAd5-HPV Vaccine (IBRX-042)
Biological/VaccineIBRX-042 administered subcutaneously as part of the experimental treatment regimen.
Nab-Paclitaxel
DrugNab-paclitaxel 100 mg/m² administered intravenously during neoadjuvant treatment cycles.
Cisplatin
DrugCisplatin 40 mg/m² administered intravenously concurrently with radiation therapy.
De-Intensified IMRT
RadiationIMRT 40 Gy, delivered once daily, 5 days/week, over 4 weeks (20 total fractions)
Standard of Care IMRT
RadiationSOC IMRT 70 Gy, delivered once daily, 5 days/week, over 7 weeks (35 total fractions)
Progression-Free Survival (PFS)
Progression-free survival (PFS) as assessed by RECIST 1.1 criteria comparing the experimental treatment arm with the standard-of-care control arm in participants with locally advanced HPV-positive oropharyngeal squamous cell carcinoma (OPSCC).
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
